Quantcast
Last updated on April 16, 2014 at 12:01 EDT

Latest obstructive coronary artery disease Stories

2013-11-25 08:27:45

- Corus® CAD Gene Expression Test Impacts Clinical Decision-Making in Primary Care Practices and Reduces Unnecessary Referrals for Cardiac Testing in this Special Population - PALO ALTO, Calif., Nov. 25, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from a multi-center, real-world registry study highlighting the clinical utility of Corus(®) CAD in evaluating suspected obstructive coronary artery...

2013-11-18 12:30:17

- Data Presented Demonstrate the Advantages of Corus® CAD in Improving Clinical Decision-Making and Reducing Diagnostic Test Overutilization in Women with Symptoms Suggestive of Obstructive Coronary Artery Disease - PALO ALTO, Calif., Nov. 18, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results from two studies reinforcing the value of Corus(®) CAD as an initial diagnostic test for the evaluation of...

2013-10-21 08:29:25

- Corus® CAD is Effective in Excluding the Diagnosis of Obstructive Coronary Artery Disease in the Primary Care Setting and Helps Reduce Unnecessary Healthcare Expense - PALO ALTO, Calif., Oct. 21, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of a multi-center, real-world registry study demonstrating the clinical utility of Corus® CAD, a blood-based gene expression test, in the evaluation of...

2013-10-10 08:29:32

- Corus® CAD Has Potential to Reduce Cardiac Diagnostic Costs in Women by More Than $500 per Patient - PALO ALTO, Calif., Oct. 10, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of two studies indicating that Corus(®) CAD, a blood-based gene expression test, may help reduce unnecessary cardiac testing and costs by aiding clinician decision-making in the evaluation of women with symptoms...

2013-09-03 08:28:48

Corus CAD Gene Expression Test Helped Cardiologists Determine Which Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease (CAD) Did Not Require Further Cardiac Testing PALO ALTO, Calif., Sept. 3, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of results from the Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern...

2013-08-26 16:23:34

- Sex-Specific Blood-based Genomic Test Helps Exclude the Diagnosis of Obstructive CAD in Symptomatic Patients - PALO ALTO, Calif., Aug. 26, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of a comprehensive review of the evidence demonstrating that Corus(®) CAD, a blood-based gene expression test, can help clinicians accurately and safely exclude obstructive coronary artery disease (CAD)...

2013-07-18 08:29:50

- Two Studies to be Presented at "What a Difference an X Makes: The State of Women's Health Research" Validate the Accuracy and Clinical Utility of Corus® CAD, the Only Sex-Specific Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., July 18, 2013 /PRNewswire/ -- CardioDx, Inc., a leader in the field of cardiovascular genomic diagnostics, today announced that the company will present two studies demonstrating the accuracy and clinical utility of...

2013-05-20 08:27:53

- Use of Corus® CAD Led to a Statistically Significant Reduction in Additional Cardiac Testing - PALO ALTO, Calif., May 20, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial in Critical Pathways in Cardiology. This prospective study conducted at Vanderbilt University...

2013-03-25 08:27:37

- Additional Data Underscore the Value of Corus CAD in Improving Primary Care Providers' (PCP) Precision at Excluding the Diagnosis of Obstructive Coronary Artery Disease in Female Patients Early in the Diagnostic Pathway - PALO ALTO, Calif., March 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced data demonstrating that Corus(®) CAD, the only clinically validated gene expression test for the assessment of...

2013-03-11 08:27:27

- Study Found that Cardiologists Changed Their Diagnostic Testing Strategy in 60 Percent of Female Patients Following Corus CAD Testing - PALO ALTO, Calif., March 11, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a prospective study that evaluated how Corus(®) CAD, a blood-based gene expression test, influenced cardiologists' patient management decisions in women with suspected obstructive coronary...